Search results
Corvus Pharmaceuticals Inc (CRVS) Q1 2024 Earnings Call Transcri
Guru Focus· 44 minutes agoFor the complete transcript of the earnings call, please refer to the full earnings call transcript. Corvus Pharmaceuticals Inc (CRVS, Financial) reported a reduced net loss in Q1 2024 of $5.7 ...
ASLAN expands research on atopic dermatitis treatment By Investing.com
Investing.com· 5 days agoASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage biopharmaceutical company, has announced a new...
Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say
Zacks via Yahoo Finance· 5 days agoAlthough the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the...
Stopping the sniffles: Don't let nasal polyps steal your scent-sibility
La Crosse Tribune· 3 days ago“Nasal polyps are soft, noncancerous growths on the nasal passages or sinus linings that can cause...
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 4 days agoKymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript May 3, 2024 Kymera...
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
Zacks via Yahoo Finance· 4 days agoKymera (KYMR) reports a narrower-than-expected loss in the first quarter. The company expects the...
Earnings call: Kymera Therapeutics reports progress in drug development By Investing.com
Investing.com· 4 days agoKymera Therapeutics, during their first quarter 2024 earnings call, provided a comprehensive update...
Small Business - Austin Daily Herald | Austin Daily Herald
Austin Daily Herald· 5 days agoFirst quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023; excluding RonapreveTM(a)(b), revenues increased 7%First quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 24% to $3.08 billion versus first